{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:28:43Z","timestamp":1791224923083,"version":"4.1.0"},"reference-count":150,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The scope of therapeutic options for the treatment of hepatocellular carcinoma (HCC) has recently been expanded by immunotherapeutic regimens. T cell-based therapies, especially in combination with other treatments have achieved far better outcomes compared to conventional treatments alone. However, there is an emerging body of evidence that eliciting T cell responses in immunotherapeutic approaches is insufficient for favorable outcomes. Immune responses in HCC are frequently attenuated in the tumor microenvironment (TME) or may even support tumor progress. Hence, therapies with immune checkpoint inhibitors or adoptive cell therapies appear to necessitate additional modification of the TME to unlock their full potential. In this review, we focus on immunotherapeutic strategies, underlying molecular mechanisms of CD8 T cell immunity, and causes of treatment failure in HCC of viral and non-viral origin. Furthermore, we provide an overview of TME features in underlying etiologies of HCC patients that mediate therapy resistance to checkpoint inhibition and discuss strategies from the literature concerning current approaches to these challenges.<\/jats:p>","DOI":"10.3390\/cells10071651","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T02:44:39Z","timestamp":1625107479000},"page":"1651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prospects and Challenges for T Cell-Based Therapies of HCC"],"prefix":"10.3390","volume":"10","author":[{"given":"Norman","family":"Woller","sequence":"first","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Anna","family":"Engelskircher","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wirth","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.crad.2017.01.013","article-title":"Loco-regional treatment of HCC: Current status","volume":"72","author":"Crocetti","year":"2017","journal-title":"Clin. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_4","first-page":"855","article-title":"Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti\u2013PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma","volume":"31","author":"Philips","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-17-0539","article-title":"Immunotherapy of Lymphoma and Myeloma: Facts and Hopes","volume":"24","author":"Pianko","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kuzume, A., Chi, S., Yamauchi, N., and Minami, Y. (2020). Immune-Checkpoint Blockade Therapy in Lymphoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155456"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shek, D., Read, S.A., Nagrial, A., Carlino, M.S., Gao, B., George, J., and Ahlenstiel, G. (2021). Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist.","DOI":"10.1002\/onco.13776"},{"key":"ref_25","first-page":"1111","article-title":"Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: The role of angiogenic factors","volume":"56","author":"Griffioen","year":"1996","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0304-3835(97)00310-8","article-title":"Endothelial CD34 is suppressed in human malignancies: Role of angiogenic factors","volume":"120","author":"Hellwig","year":"1997","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","article-title":"Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape","volume":"3","author":"Chouaib","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the Immune Response by Pro-Angiogenic Factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fonc.2013.00231","article-title":"Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes","volume":"3","author":"Bellone","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_33","first-page":"821","article-title":"Expression characteristics of HIF-1\u03b1 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma","volume":"11","author":"Li","year":"2011","journal-title":"Hepat. Mon."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"v875","DOI":"10.1093\/annonc\/mdz394.030","article-title":"Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The Intersection between Tumor Angiogenesis and Immune Suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti\u2013PD-1 Therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-019-0636-8","article-title":"Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma","volume":"11","author":"Mohr","year":"2019","journal-title":"Genome Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2201352a0","article-title":"Cellular and Humoral immunity to Different Types of Human Neoplasms","volume":"220","author":"Pierce","year":"1968","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The Three Es of Cancer Immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection","volume":"25","author":"Gao","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11901-020-00553-7","article-title":"Genomic Landscape of HCC","volume":"19","author":"Adeniji","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2012.09.027","article-title":"Next generation sequencing reveals genetic landscape of hepatocellular carcinomas","volume":"340","author":"Li","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1136\/gutjnl-2019-318912","article-title":"Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas","volume":"68","author":"Zhang","year":"2019","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.29904","article-title":"Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification","volume":"68","author":"Kurebayashi","year":"2018","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/liv.14192","article-title":"Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications","volume":"39","author":"Cariani","year":"2019","journal-title":"Liver Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1038\/s41598-018-21937-2","article-title":"The immune contexture of hepatocellular carcinoma predicts clinical outcome","volume":"8","author":"Foerster","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/s41598-018-24437-5","article-title":"Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma","volume":"8","author":"Stift","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: The tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.31206","article-title":"Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation","volume":"72","author":"Itoh","year":"2020","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell Dysfunction and Exhaustion in Cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2014.08.008","article-title":"A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C","volume":"62","author":"Sekyere","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.31466","article-title":"Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"key":"ref_70","first-page":"3212","article-title":"Immune checkpoint targeting TIGIT in hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.4049\/jimmunol.1300271","article-title":"Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma","volume":"190","author":"Goding","year":"2013","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1746573","DOI":"10.1080\/2162402X.2020.1746573","article-title":"Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma","volume":"9","author":"Liu","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chaoul, N., Mancarella, S., Lupo, L., Giannelli, G., and Dituri, F. (2020). Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12030627"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Patel","year":"2012","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1038\/cti.2016.51","article-title":"MAIT cells: New guardians of the liver","volume":"5","author":"Kurioka","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Salomone, F., Galvano, F., and Volti, G.L. (2017). Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients, 9.","DOI":"10.3390\/nu9010085"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/105221617X15046391179559","article-title":"Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis","volume":"18","author":"Dranoff","year":"2018","journal-title":"Gene Expr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12688\/f1000research.6368.2","article-title":"I drink for my liver, Doc: Emerging evidence that coffee prevents cirrhosis","volume":"4","author":"Feld","year":"2015","journal-title":"F1000Research"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/bjc.2013.390","article-title":"Expression pattern of tumour-associated antigens in hepatocellular carcinoma: Association with immune infiltration and disease progression","volume":"109","author":"Liang","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Hofmann, M., Tauber, C., Hensel, N., and Thimme, R. (2021). CD8+ T Cell Responses during HCV Infection and HCC. J. Clin. Med., 10.","DOI":"10.3390\/jcm10050991"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00535-009-0155-2","article-title":"Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma","volume":"45","author":"Hiroishi","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","article-title":"Human tumor antigens recognized by T lymphocytes","volume":"183","author":"Boon","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1074-7613(00)80028-X","article-title":"A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens","volume":"10","author":"Rosenberg","year":"1999","journal-title":"Immunity"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: An expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/hep.21203","article-title":"Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma","volume":"43","author":"Mizukoshi","year":"2006","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kaji, K., Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Fushimi, K., Nakagawa, H., Yamada, K., Terashima, T., and Kitahara, M. (2017). Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170291"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.22535","article-title":"Comprehensive analysis of the \u03b1-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma","volume":"48","author":"Thimme","year":"2008","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_101","first-page":"2739","article-title":"Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma","volume":"19","author":"Li","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti\u2013PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Bresnahan","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000490360","article-title":"HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection","volume":"8","author":"Sekyere","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.celrep.2016.10.086","article-title":"Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer","volume":"17","author":"Knocke","year":"2016","journal-title":"Cell Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","article-title":"Steatohepatitis Impairs T-cell\u2013Directed Immunotherapies Against Liver Tumors in Mice","volume":"160","author":"Heinrich","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_109","unstructured":"The Cancer Genome Atlas Research Network (2017). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 169, 1327\u20131341."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2009.08.008","article-title":"Immune tolerance: What is unique about the liver","volume":"34","author":"Tiegs","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","article-title":"Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression","volume":"30","author":"Eggert","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"100777","DOI":"10.1016\/j.tranon.2020.100777","article-title":"Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation","volume":"13","author":"Kitahara","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ocker, M., Mayr, C., Kiesslich, T., Stintzing, S., and Neureiter, D. (2021). Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 13.","DOI":"10.3390\/cancers13071558"},{"key":"ref_115","first-page":"3181","article-title":"A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer","volume":"63","author":"Wirth","year":"2003","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Alexander, M., Culos, K., Roddy, J., Shaw, R., Bachmeier, C., Shigle, T.L., and Mahmoudjafari, Z. (2021). Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplant. Cell. Ther.","DOI":"10.1016\/j.jtct.2021.01.014"},{"key":"ref_128","first-page":"690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Rochigneux, P., Chanez, B., De Rauglaudre, B., Mitry, E., Chabannon, C., and Gilabert, M. (2021). Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 13.","DOI":"10.3390\/cancers13020271"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen landscape dynamics during human melanoma\u2013T cell interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"655697","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","article-title":"A Phase I\/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four \u03b1-Fetoprotein Peptides","volume":"12","author":"Butterfield","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1053\/j.gastro.2017.02.001","article-title":"Association Between High-Avidity T-Cell Receptors, Induced by \u03b1-Fetoprotein\u2014Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma","volume":"152","author":"Nakagawa","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Greten, T.F., Forner, A., Korangy, F., N\u2019Kontchou, G., Barget, N., Ayuso, C., Ormandy, L.A., Manns, M.P., Beaugrand, M., and Bruix, J. (2010). A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-209"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2015.04.031","article-title":"Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma","volume":"364","author":"Mizukoshi","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I Trial of a Glypican-3\u2013Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1349-7006.2011.01896.x","article-title":"HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells","volume":"102","author":"Yoshikawa","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/mt.2013.277","article-title":"In Vivo Proof of Concept of Adoptive Immunotherapy for Hepatocellular Carcinoma Using Allogeneic Suicide Gene-modified Killer Cells","volume":"22","author":"Leboeuf","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cam4.1459","article-title":"MRI-guided interventional natural killer cell delivery for liver tumor treatment","volume":"7","author":"Su","year":"2018","journal-title":"Cancer Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","article-title":"Management of immune related adverse events induced by immune checkpoint inhibition","volume":"456","author":"Teufel","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_145","first-page":"21","article-title":"CAR T-Cell Therapy: Adverse Events and Management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI45585","article-title":"Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice","volume":"121","author":"Woller","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/7\/1651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:22Z","timestamp":1760163862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/7\/1651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":150,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cells10071651"],"URL":"https:\/\/doi.org\/10.3390\/cells10071651","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}